share_log

Exicure | 8-K: Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure | 8-K: Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure | 8-K：Exicure, Inc. 签订了130万美元和870万美元股权融资的收购协议，并公布了2024年第三季度财务业绩
美股SEC公告 ·  2024/11/15 05:31

Moomoo AI 已提取核心信息

Exicure has entered into two stock purchase agreements with HiTron Systems Inc., totaling $10 million. The initial agreement, executed on November 12, involves selling 433,000 shares at $3.00 per share for $1.3 million, expected to close within 10 days. The subsequent agreement dated November 13 involves issuing 2.9 million shares for $8.7 million, subject to stockholder approval.The agreements grant HiTron board nomination rights, with two initial board seats following the first closing and additional proportional representation after the subsequent investment. The company reported Q3 2024 results with a net loss of $1.1 million, improved from $5.3 million loss in Q3 2023, while cash position stood at $0.3 million as of September 30, 2024.The company faces continued listing challenges on Nasdaq and has requested an extension through December 17, 2024. Management indicates current cash is insufficient for operations, emphasizing the critical need for additional funding. The proceeds will be used for working capital, general corporate purposes, and business development.
Exicure has entered into two stock purchase agreements with HiTron Systems Inc., totaling $10 million. The initial agreement, executed on November 12, involves selling 433,000 shares at $3.00 per share for $1.3 million, expected to close within 10 days. The subsequent agreement dated November 13 involves issuing 2.9 million shares for $8.7 million, subject to stockholder approval.The agreements grant HiTron board nomination rights, with two initial board seats following the first closing and additional proportional representation after the subsequent investment. The company reported Q3 2024 results with a net loss of $1.1 million, improved from $5.3 million loss in Q3 2023, while cash position stood at $0.3 million as of September 30, 2024.The company faces continued listing challenges on Nasdaq and has requested an extension through December 17, 2024. Management indicates current cash is insufficient for operations, emphasizing the critical need for additional funding. The proceeds will be used for working capital, general corporate purposes, and business development.
Exicure与HiTron Systems Inc.签订了两份股票购买协议，总金额为1000万美元。第一次协议于11月12日签署，涉及以每股3.00美元出售433,000股，预计在10天内完成，金额为130万美元。第二份协议于11月13日签署，涉及发行290万股，金额为870万美元，需经股东批准。这些协议授予HiTron董事会提名权，首次交易后有两个董事会席位，后续投资后将增加相应的比例代表权。公司报告了2024年第三季度的业绩，净亏损为110万美元，较2023年第三季度的530万美元亏损有所改善，截至2024年9月30日，现金状况为30万美元。公司面临纳斯达克的持续上市挑战，并已请求延长至2024年12月17日。管理层表示，目前的现金不足以维持运营，强调了对额外资金的迫切需求。筹集的资金将用于流动资金、一般企业用途和业务发展。
Exicure与HiTron Systems Inc.签订了两份股票购买协议，总金额为1000万美元。第一次协议于11月12日签署，涉及以每股3.00美元出售433,000股，预计在10天内完成，金额为130万美元。第二份协议于11月13日签署，涉及发行290万股，金额为870万美元，需经股东批准。这些协议授予HiTron董事会提名权，首次交易后有两个董事会席位，后续投资后将增加相应的比例代表权。公司报告了2024年第三季度的业绩，净亏损为110万美元，较2023年第三季度的530万美元亏损有所改善，截至2024年9月30日，现金状况为30万美元。公司面临纳斯达克的持续上市挑战，并已请求延长至2024年12月17日。管理层表示，目前的现金不足以维持运营，强调了对额外资金的迫切需求。筹集的资金将用于流动资金、一般企业用途和业务发展。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。